



Universiteit
Leiden
The Netherlands

Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease

Bukkems, L.H.; Heijdra, J.M.; Jager, N.C.B. de; Hazendonk, H.C.A.M.; Fijnvandraat, K.; Meijer, K.; ... ; OPTI-CLOT Study Grp

Citation

Bukkems, L. H., Heijdra, J. M., Jager, N. C. B. de, Hazendonk, H. C. A. M., Fijnvandraat, K., Meijer, K., ... Mathot, R. A. A. (2021). Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. *Blood Advances*, 5(5), 1513-1522. doi:10.1182/bloodadvances.2020003891

Version: Publisher's Version
License: [Leiden University Non-exclusive license](#)
Downloaded from: <https://hdl.handle.net/1887/3230143>

Note: To cite this publication please use the final published version (if applicable).

Population pharmacokinetics of the von Willebrand factor–factor VIII interaction in patients with von Willebrand disease

Laura H. Bukkems,¹ Jessica M. Heijdra,² Nico C. B. de Jager,¹ Hendrika C. A. M. Hazendonk,² Karin Fijnvandraat,³ Karina Meijer,⁴ Jeroen C. J. Eikenboom,⁵ Britta A. P. Laros-van Gorkom,⁶ Frank W. G. Leebeek,⁷ Marjon H. Cnossen,^{2,*} and Ron A. A. Mathôt,^{1,*} for the OPTI-CLOT Study Group

¹Hospital Pharmacy–Clinical Pharmacology, Amsterdam University Medical Center (UMC), University of Amsterdam, Amsterdam, The Netherlands; ²Department of Pediatrics, Erasmus MC–Sophia Children's Hospital, University Medical Center Rotterdam, The Netherlands; ³Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; ⁴Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; ⁵Division of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands; ⁶Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands; and ⁷Department of Hematology, Erasmus MC, University Medical Center Rotterdam, The Netherlands

Key Points

- The developed population PK model could adequately describe the interaction between VWF and FVIII in perioperative patients with VWD.
- Presence of VWF decreases FVIII clearance, clarifying FVIII accumulation over time as observed after multiple VWF/FVIII concentrate doses.

Recent studies have reported that patients with von Willebrand disease treated perioperatively with a von Willebrand factor (VWF)/factor VIII (FVIII) concentrate with a ratio of 2.4:1 (Humate P/Haemate P) often present with VWF and/or FVIII levels outside of prespecified target levels necessary to prevent bleeding. Pharmacokinetic (PK)-guided dosing may resolve this problem. As clinical guidelines increasingly recommend aiming for certain target levels of both VWF and FVIII, application of an integrated population PK model describing both VWF activity (VWF:Act) and FVIII levels may improve dosing and quality of care. In total, 695 VWF:Act and 894 FVIII level measurements from 118 patients (174 surgeries) who were treated perioperatively with the VWF/FVIII concentrate were used to develop this population PK model using nonlinear mixed-effects modeling. VWF:Act and FVIII levels were analyzed simultaneously using a turnover model. The protective effect of VWF:Act on FVIII clearance was described with an inhibitory maximum effect function. An average perioperative VWF:Act level of 1.23 IU/mL decreased FVIII clearance from 460 mL/h to 264 mL/h, and increased FVIII half-life from 6.6 to 11.4 hours. Clearly, in the presence of VWF, FVIII clearance decreased with a concomitant increase of FVIII half-life, clarifying the higher FVIII levels observed after repetitive dosing with this concentrate. VWF:Act and FVIII levels during perioperative treatment were described adequately by this newly developed integrated population PK model. Clinical application of this model may facilitate more accurate targeting of VWF:Act and FVIII levels during perioperative treatment with this specific VWF/FVIII concentrate (Humate P/Haemate P).

Introduction

von Willebrand disease (VWD) is an autosomally inherited bleeding disorder, with an estimated prevalence between 0.6 and 1.3%.¹ Patients with VWD suffer from bleeding caused by von Willebrand factor (VWF) deficiency or dysfunction, leading to defects in the primary hemostasis as VWF promotes platelet adhesion and aggregation.² VWF also plays a role in the secondary hemostasis as it acts as chaperone protein for factor VIII (FVIII), protecting it from degradation and clearance in the circulation. Therefore, patients with VWD often also present with reduced FVIII levels. VWD is categorized into 3

Submitted 24 November 2020; accepted 21 January 2021; published online 8 March 2021. DOI 10.1182/bloodadvances.2020003891.

*M.H.C. and R.A.A.M. are joint last authors.

For data sharing, the corresponding author, Ron A. A. Mathôt, can be contacted at r.mathot@amsterdamumc.nl. An earlier descriptive publication with a similar data set is Hazendonk et al.¹⁴

The full-text version of this article contains a data supplement.

© 2021 by The American Society of Hematology

types: type 1 patients are characterized by a partial quantitative VWF deficiency, type 2 patients by functional VWF defects, and type 3 patients by a complete quantitative deficiency.²

Treatment of VWD is usually on demand and focuses on normalization of VWF and FVIII levels in critical situations such as surgery, child delivery, acute bleeding, and/or trauma.³ A therapeutic increase of VWF and FVIII levels can be achieved by administration of desmopressin, which stimulates the endogenous release of VWF and subsequently increases circulating FVIII, or by IV infusion of a VWF-containing concentrate when desmopressin is contraindicated or desmopressin response is insufficient.^{4,5} Most plasma-derived VWF-containing concentrates also contain FVIII, as acute situations necessitate readily available FVIII for adequate hemostasis.^{6,7} However, during prolonged treatment with these concentrates, FVIII accumulates as FVIII production and secretion are not affected in VWD, thereby inducing a hypothetical risk of thrombosis.^{8,9} Factor concentrates with varying VWF activity (VWF:Act)/FVIII ratios are available, and several studies have indicated that repeated dosing with VWF/FVIII concentrates with a ratio of >1 results in less FVIII accumulation if VWF concentrate dosing is based only on VWF levels.^{7,10,11} A commonly used plasma-derived VWF/FVIII concentrate is Humate P or Haemate P (CSL Behring, Marburg, Germany), which has a VWF:Act/FVIII ratio of 2.4:1.^{12,13} Nonetheless, also with this specific concentrate, FVIII accumulation is observed after perioperative treatment.^{14,15}

Hazendonk et al have reported that, respectively, 65% and 91% of trough VWF:Act and FVIII levels in patients with type 1 VWD treated with Humate P during surgery were ≥ 0.20 IU/mL higher than predetermined target levels as prescribed in clinical guidelines.¹⁴ This results in higher treatment costs than necessary and an increased risk of adverse events.¹⁴ On the other hand, this study also observed 7 VWF:Act levels and FVIII levels of 5 patients below the prespecified target levels during the first 36 hours after surgery, thereby increasing bleeding risk. The wide variability in achieved levels is due to the large interindividual variability (IIV) in the pharmacokinetics (PK) of both exogenous and endogenous VWF and FVIII.^{12,14,16} A possible solution for this large variability in achieved VWF and FVIII levels is PK-guided dosing, which uses maximum a posteriori Bayesian estimation to determine individual PK parameters that can be used to calculate an adequate dose to achieve a target level. The application of this approach for perioperative dosing with this VWF/FVIII concentrate has been examined in 2 earlier studies.^{17,18} The first prospective multicenter study showed that it is feasible to determine the loading dose of a VWF/FVIII concentrate based on individual PK of VWF.¹⁷ Contrastingly, in the study by Di Paolo et al, the in vivo recovery of the individual PK profile performed before surgery did not match the in vivo recovery observed in the perioperative period, indicating that PK-guided dosing is less beneficial.¹⁸ However, data in this study were analyzed using a standard 2-compartment model without taking prior population knowledge or the influence of covariates into account. Development of a population PK model, which is based on data from a population and describes the typical PK parameters with corresponding IIV and intraindividual variability, could possibly improve the PK-guided dosing approach for patients with VWD treated with this VWF/FVIII concentrate perioperatively. We have recently developed a population PK model describing FVIII PK after VWF/FVIII concentrate (ratio 2.4:1) administration, enabling perioperative PK-guided dosing based on FVIII target

levels.¹⁹ However, as several clinical guidelines advise target levels for both VWF and FVIII to ensure adequate hemostasis, application of an integrated population PK model to predict VWF:Act as well as FVIII levels may allow for more accurate perioperative dosing and therefore improve quality of care.^{1,20,21} In addition, this model may also give insight into the mechanisms of FVIII accumulation observed in these patients. Therefore, the aim of our study was to develop the first population PK model for perioperative VWF/FVIII concentrate (ratio 2.4:1) dosing that describes the interaction between VWF and FVIII in patients with VWD.

Methods

Data collection

We used data from a retrospective multicenter study to develop this integrated population PK model.¹⁴ The data set included patients with VWD who underwent surgery in 1 of 5 academic hemophilia treatment centers in The Netherlands between 2000 and 2018. All patients received multiple perioperative doses of a plasma-derived VWF-containing concentrate with a VWF/FVIII ratio of 2.4:1 (Humate P or Haemate P) and were included in the data set if at least 2 perioperative VWF:Act and FVIII level measurements were available. Patients were excluded if other hemostatic disorders were present or if desmopressin was concomitantly used. Dose adjustments were generally based on FVIII levels, as FVIII results were usually more rapidly available. All FVIII levels were measured by a 1-stage assay, whereas different centers performed different VWF:Act assays: 4 centers used a VWF ristocetin cofactor (VWF:RCo) assay, whereas 1 center used different assays over time (VWF:RCo assay from 2000 to 2005; monoclonal antibody [VWF antibody (VWF:Ab)] assay from 2005 to 2012), and a VWF glycoprotein 1b binding (VWF:GP1bM) assay from 2012 onward. More specifications of these assays are detailed in supplemental Methods. Additional information, such as patient characteristics and surgical characteristics, were collected from electronic patient files. All data were collected following Good Clinical Practice and Dutch regulations. Informed consent was not obtained, as anonymized, retrospective data were used as reported in an earlier publication.¹⁴

Population PK modeling

A population PK model describing VWF:Act and FVIII PK after VWF/FVIII concentrate administration was constructed using nonlinear mixed-effect modeling software (NONMEM version 7.4.2; ICON Development Solution). A population PK model considers data from a whole population simultaneously instead of analyzing patients separately. Herewith, enabling simultaneous analyses of patients where PK differences are expected, such as with patients with different types of VWD. This technique can handle sparse data with random sampling times, as was the case in our retrospective clinical data set.

We used turnover models to describe the change of endogenous and exogenous VWF:Act and FVIII levels over time. This method enables handling of endogenous baseline concentrations in PK modeling, as it is able to correct for analytic assay variability of the measured endogenous baseline level; this cannot be done with the frequently used baseline subtraction method.^{22,23} First, separate PK models for VWF:Act and FVIII were developed. These models were then combined and the interaction between VWF:Act and FVIII was added. An inhibitory maximal effect ($I_{\max}$) function relating

VWF:Act levels and FVIII clearance was incorporated to describe the inhibitory effect of the VWF:Act levels on FVIII elimination.

During model development, the number of compartments, inclusion of IIV, interoccasion variability, and residual error structure were evaluated. The incorporation of a separate residual error for VWF levels measured by VWF:RCO and VWF levels measured by other assays (VWF:GP1bM or VWF:Ab) was tested to correct for the use of different analysis methods. As both children and adults were included in the data set and a wide range of weights was present, allometric scaling to body weight was applied.

Covariate analysis

Patient characteristics or surgical characteristics may potentially explain part of the IIV observed in PK parameters. To identify these characteristics, a covariate analysis was performed using forward inclusion and backward elimination. The following patient characteristics were tested: age, sex, VWD type as diagnosed by the local center, blood group, and physical status as determined by the American Society of Anesthesiologists (ASA) classification.²⁴ The influence of liver and kidney parameters was evaluated by the following covariates: alanine aminotransferase, aspartate aminotransferase, γ glutamyl transferase, alkaline phosphatase, lactate dehydrogenase, albumin, creatinine, and urea levels. Surgical characteristics included duration and severity of the procedure.²⁵ Administration of comedication such as tranexamic acid, non-steroidal anti-inflammatory drugs, or heparin was evaluated in the covariate analysis. First, covariates were included univariately to statistically select potential covariates. Thereafter, we performed a forward inclusion and backward elimination procedure. Finally, inclusion of interoccasion variability was evaluated and the final population PK model was constructed. More in-depth details of the modeling process can be found in supplemental Methods.

Model evaluation

To evaluate the adequacy of the population PK models to predict the VWF:Act and FVIII levels, goodness-of-fit plots were inspected. The final model was internally validated using a visual predictive check (VPC). One thousand data sets were simulated with the final model and the simulated levels were compared with the observed levels. Additionally, a bootstrap was performed to test the robustness of the model. During the bootstrap analysis, 1000 new data sets were randomly created from the original data set and the model was re-estimated using the newly created data sets.

Results

The data set consisted of 118 patients with different types of VWD, aged 1 to 82 years, who underwent 174 surgeries (Table 1). Eight children (<18 years) were included, with a median age of 14 years (range, 1-17 years) and median weight of 53.5 kg (range, 8.8-107 kg). Patients received a median of 5 doses of the VWF/FVIII concentrate per perioperative period, and a total of 695 VWF:Act and 894 FVIII levels were available. None of the FVIII levels were below the quantification limit (<0.01 IU/mL), but 3 VWF:Act levels were below the quantification limit of 0.20 IU/mL. These VWF:Act levels were excluded from analysis as the percentage of samples below the quantification limit was only 0.4%. A median of 4 VWF:Act levels and 5 FVIII levels were collected per perioperative period. These samples were taken between 171 hours before the start of surgery and 524 hours after surgery; but 96% of the samples were

Table 1. Patient characteristics

Demographics	Median (range) or no. (%)	No. of patients*
No. of patients	118	—
Sex, male	40 (34)	118
Age, y	49 (0.5-82)	118
Body weight, kg	77.0 (8.8-118.0)	118
Height, cm	172.0 (69.0-194.0)	113
Historical baseline FVIII level, IU/mL	0.41 (0.01-0.97)	118
Historical baseline VWF:Act level, IU/mL	0.15 (0.00-0.58)	118
Historical baseline VWF:Ag level, IU/mL	0.28 (0.00-0.93)	118
Blood group 0	59 (52)	113
VWD type		118
Type 1	57 (48)	
Type 2A	32 (27)	
Type 2B	9 (8)	
Type 2M	11 (9)	
Type 2N	3 (3)	
Type 3	6 (5)	
Surgery information		
No. of surgeries, occasions	174	—
Duration of surgery, min	67.5 (7.0-470.0)	174
Severity of surgery	—	174
Minor	50 (29)	
Major	124 (71)	
ASA classification per surgery	—	154
II	127 (82)	
III	26 (17)	
IV	1 (1)	
Treatment information		
Bolus dose in FVIII, IU/kg, n = 1036	20.8 (5.5-66.1)	
CID in FVIII, IU/h/kg, n = 51	1.06 (0.19-4.17)	
No. of doses per surgery	5 (1-30)	
Tranexamic acid during surgery	68 (39)	
NSAID use during surgery	9 (5)	
Heparin use during surgery	71 (41)	

—, data not available; CID, continuous infusion dose; NSAID, nonsteroidal anti-inflammatory drug; VWF:Ag, von Willebrand factor antigen.

*Data available.

collected within 168 hours after surgery. After the first perioperative VWF/FVIII concentrate dose, the median FVIII level was 1.30 IU/mL (range 0.41-3.64 IU/mL), which accumulated to a median FVIII level of 1.80 IU/mL (range: 0.59-4.21 IU/mL) on day 5. The VPC, which is explained later in "Results," also illustrates the (prediction-corrected) observed VWF:Act and FVIII levels over time (Figure 1).

Population PK model

Time profiles of both VWF:Act and FVIII were described using turnover models. In these models, the change in endogenous VWF and FVIII levels over time was described with a zero-order production rate, k_{in} , and a first order elimination rate, k_{out} . Upon




Figure 1. Prediction corrected visual predictive check of the final integrated VWF/FVIII population PK model. The median and 2.5th and 97.5th percentile of the observed levels (black dots) at each bin are presented as the red line and the blue lines, respectively. The red and blue shaded boxes represent the median and 2.5th and 97.5th percentile of the 1000 simulated prediction corrected observations at each bin, respectively. (A) FVIII. (B) VWF:Act.

administration of the factor concentrate, VWF and FVIII were injected in the respective central compartments. The interaction between VWF and FVIII was described by an inhibitory effect of VWF:Act on FVIII clearance. An $I_{\max}$ relation was chosen to describe this relationship, following equation 1: inhibition = $1 - \frac{(I_{\max} \times C_{VWF})}{(IC_{50} + C_{VWF})}$ (1), in which C_{VWF} represents the VWF level, $I_{\max}$ the maximal inhibitory effect on FVIII clearance, and IC_{50} the VWF level at which 50% FVIII clearance inhibition was established. A visual representation of the model can be found in Figure 2.

In 77 surgeries, the VWF:Act level before the first VWF/FVIII concentrate infusion (preadministration level) was higher (0.26 IU/mL [range, 0.01-3.74]) than the historical baseline (lowest level ever measured; 0.15 IU/mL [range, 0.00-0.58]). The preadministration FVIII level (0.68 IU/mL [range, 0.01-3.11]) was also higher than the historical baseline level (0.41 IU/mL [range, 0.01-0.97]) in 98 surgeries. In the turnover models, the preadministration VWF:Act and FVIII levels were considered as baseline values instead of the historical baseline levels, assuming that the increase in endogenous VWF:Act and FVIII levels was permanent and levels would return to the preadministration level after the perioperative period.

The structural model consisted of 1-compartment turnover models for both VWF:Act and FVIII (Figure 2). Typical values for VWF (1) preadministration baseline, (2) clearance, and (3) volume of distribution with corresponding IIV values (percentage) were (1) 0.42 IU/mL (126.4%), (2) 262 mL/h (55.3%), and (3) 4990 mL (25.2%) for a patient of 70 kg (Table 2). Using the integrated turnover model, typical values for FVIII (1) preadministration baseline, (2) clearance, and (3) volume of distribution were (1) 0.77 IU/mL (32.2%), (2) 460 mL/h (81.5%), and (3) 4350 mL. These values reflect the theoretical situation in which VWF is absent. VWF inhibited FVIII clearance with an IC_{50} value of 1.65 IU/mL. An average perioperative VWF:Act level of 1.23 IU/mL decreased FVIII clearance from 460 mL/h to 264 mL/h and increased FVIII elimination half-life from 6.6 hours to 11.4 hours.

Covariate analysis

During univariate selection, the following associations were statistically significant ($P < .05$): surgery duration on VWF clearance; sex on VWF volume of distribution; VWD type; ASA score and age on VWF baseline; VWD type on FVIII clearance; and ASA score, age, and blood group 0 on baseline FVIII. After forward inclusion and backward elimination, only duration of surgery on VWF clearance, VWD type and ASA score on VWF preadministration baseline, and VWD type on FVIII clearance were retained in the model ($P < .01$). Increase in surgery duration was associated with a decrease of VWF clearance. Specifically, when the duration of surgery increased from 45 to 110 minutes (interquartile range), VWF clearance decreased from 284 to 219 mL/h. The VWF preadministration baseline of VWD type 2 and type 3 patients was 61.0% and 81.8% lower than the VWF baseline of type 1 patients. For patients with an ASA score of III or IV, a 53% higher VWF:Act preadministration baseline was observed than for patients with ASA




Figure 2. Schematic overview of the integrated population PK model consisting of 1-compartment models described by central volume of distribution (V) and clearance (CL). The VWF activity inhibits the clearance of FVIII and is described by an $I_{\max}$ relationship, where IC_{50} describes the VWF activity resulting in 50% of the maximal inhibitory effect. The change in endogenous VWF and FVIII amounts over time was described with a turnover model with zero-order production rate k_{in} .

Table 2. PK parameters for the structural model, final model, and bootstrap analysis

Parameter	Structural model		Final model		Bootstrap	
	Estimate	RSE, % (Shr)	Estimate	RSE, % (Shr)	Estimate	95% CI
CL FVIII, mL/70 kg/h	460	39.1	1170	37.1	1188	546-5801
V FVIII, mL/70 kg	4350	7.3	4440	6.5	4414	3940-5178
Baseline FVIII, IU/mL	0.77	15.0	0.64	6.9	0.64	0.50-0.80
CL VWF, mL/70 kg/h	262	7.5	252	6.3	255	228-291
V VWF, mL/70 kg	4990	4.1	5060	3.9	5058	4654-5570
Baseline VWF, IU/mL	0.42	11.3	0.68	14.1	0.68	0.52-0.89
IC ₅₀ , IU/mL	1.65	39.7	1.10	15.5	1.08	0.67-1.84
I _{max}	1 (fixed)	—	1 (fixed)	—	1	1-1
IIV, CV%						
IIV on CL VWF	55.3	11.3 (27.5)	49.9	12.6 (25.7)	48.2	32.0-63.5
IIV on V VWF	25.2	21.1 (35.4)	27.6	11.3 (31.4)	26.5	17.5-34.1
IIV on CL FVIII	81.5	25.6 (26.6)	85.4	13.8 (32.4)	79.8	46.7-314.0
IIV on base FVIII	32.2	15.6 (11.4)	27.8	12.0 (14.3)	27.4	20.5-35.7
IIV on base VWF	126.4	9.8 (10.5)	85.2	11.1 (15.1)	83.4	60.9-111.2
Correlation IIV base FVIII and base VWF	55.4	0.0767	32.4	0.032	32.2	−2.9 to 60.3
Residual variability						
Proportional error FVIII, %	19.4	8.0	18.7	7.4	18.5	15.3-21.1
Additive error FVIII, IU/mL	0.13	25.6	0.13	22.7	0.13	0.06-0.18
Proportional error VWF:RCO, %	26.7	7.6	27.0	7.0	26.9	22.9-30.6
Proportional error VWF:Ab and VWF:Gp1bM, %	23.0	6.6	22.6	6.3	22.7	19.6-25.4
Covariate relations						
Duration of surgery on CL VWF	—	—	−0.29	30.6	−0.29	−0.56 to −0.18
VWD type 2 on baseline VWF	—	—	0.39	18.8	0.40	0.27-0.57
VWD type 3 on baseline VWF	—	—	0.18	65.4	0.19	0.04-1.01
ASA score III/IV on baseline VWF	—	—	1.53	15.4	1.48	1.15-2.29
VWD type 2 on CL FVIII	—	—	0.44	26.4	0.44	0.17-0.72
VWD type 3 on CL FVIII	—	—	0.34	52.8	0.33	0.08-1.20

Of the 1000 data subsets used for bootstrap analysis, 849 runs were successful.

Formula PK parameters, final model:

$$CL\ VWF = \theta_{CL} * (weight_i/70)^{0.75} * (surgery\ duration_i/68)^{-0.29} * e^{\eta_{CL}};$$

$$V\ VWF = \theta_V * (weight_i/70)^1 * e^{\eta_V};$$

$$BASE\ VWF = \theta_{BASE} * 1.53^{ASA\ class\ 3,4} * 0.39^{VWD\ type\ 2} * 0.18^{VWD\ type\ 3} * e^{\eta_{BASE}};$$

$$CL\ FVIII = \theta_{CL} * (weight_i/70)^{0.75} * 0.44^{VWD\ type\ 2} * 0.34^{VWD\ type\ 3} * e^{\eta_{CL}};$$

$$V\ FVIII = \theta_V * (weight_i/70)^1;$$

$$BASE\ FVIII = \theta_{BASE} * e^{\eta_{BASE}}.$$

—, data not available; CI, confidence interval; CL, clearance; CV, coefficient of variation calculated as $\sqrt{(\exp(\omega^2) - 1) \times 100}$; RSE, relative standard error; Shr, shrinkage; V, volume of distribution.

score II. All patients had at least ASA score II, as VWD is a mild systemic disease and only completely healthy patients classify as ASA I. Patients with VWD type 2 and type 3 had a 56.4 and 65.7% lower FVIII clearance, respectively, compared with type 1.

Model evaluation

The goodness-of-fit plots of the final model demonstrate that the model describes VWF:Act and FVIII levels adequately (Figure 3). The VPC shows similar adequate model performance (Figure 1). Finally, the estimates and 95% confidence intervals of the bootstrap confirm robustness of the model (Table 2).

Clinical application of the novel population PK model

To demonstrate the clinical application of the newly developed model, a 33-year-old man (69 kg) with type 3 VWD who underwent ankle surgery while being treated with the VWF/FVIII concentrate (ratio 2.4:1) was fitted with the newly developed integrated VWF/FVIII model retrospectively. The patient was not included in the original data set and informed consent of the patient was obtained. An initial dose of ~50 IU/kg, followed by doses of ~25 IU/kg every 12 hours, following clinical guidelines pursuing prespecified VWF and FVIII target levels, were administered to the patient.²⁰ Figure 4A confirms that the measured FVIII and VWF levels of this patient were adequately




Figure 3. Goodness-of-fit plots of the final population PK model. Red circles represent FVIII levels, whereas blue triangles represent VWF:Act levels. (A-B) The observed level is compared with the individual predicted (A) and population predicted levels (B). (C-D) The conditional weighted residuals (CWRES) are plotted to the population prediction (C) and the time before/after surgery (D).

described by the newly developed integrated VWF/FVIII population PK model, including the observed accumulating FVIII levels. Only the initial preadministration FVIII level was estimated higher than observed, probably caused by the fact that only a few type 3 patients with a low endogenous FVIII baseline were included in the model. Interestingly, during the first 36 hours after the start of surgery, the VWF target level of >0.80 IU/mL, as prespecified in the clinical guidelines to prevent bleeding, was not achieved after administration of the dosing scheme as described herein, although no bleeding or adverse events occurred.²⁰

Thereafter, the individual dosing scheme that would have been necessary to reach the prespecified VWF and FVIII target levels was calculated. This advised dosing scheme was composed based on individual PK parameters retrieved from the available preoperative PK profile in which VWF and FVIII levels were measured before and at 3 time points after infusion of 25 IU/kg of the VWF/FVIII concentrate. When dosing was based on the individual PK parameters (PK-guided dosing), higher doses would have been necessary for this unique patient to reach the specified target levels (Figure 4B).

Discussion

A novel population PK model was successfully developed that describes VWF:Act and FVIII levels simultaneously, illustrating their physiological interaction, after perioperative dosing with a VWF/FVIII concentrate (ratio 2.4:1) in patients with VWD. In literature, the protective effect of VWF on FVIII metabolism and clearance has not yet been quantified in a population PK model. Moreover, the model demonstrates that the presence of VWF increased the half-life of FVIII, thereby clarifying FVIII accumulation as is generally observed after perioperative treatment with this VWF/FVIII concentrate.

In this integrated population PK model, the observed VWF:Act and FVIII levels over time were both described by 1-compartment turnover models. The interaction between both coagulation proteins was captured by an $I_{\max}$ relation function connecting VWF:Act to FVIII clearance. The PK parameters obtained in this integrated population PK model are consistent with the values described in literature. The developed population PK model predicts a FVIII half-life of 11.4 hours in the presence of 1.23 IU/mL VWF:Act, which is similar to the average FVIII half-life of 12 hours as described in literature.^{26,27} In patients with type 3 and type 2N VWD, the FVIII half-life without VWF presence or VWF binding can be assessed.




Figure 4. Clinical example of the fit using the developed integrated VWF-FVIII population PK model. This 33-year-old patient of 69 kg is treated with VWF/FVIII concentrate (ratio 2.4:1) during ankle surgery. The VWF:Act levels (blue lines) and FVIII levels (red lines) are estimated using the new integrated VWF-FVIII population PK model. The observed VWF:Act levels are shown by the blue dots and the observed FVIII levels are shown by the red dots. The dotted lines represent the VWF and FVIII target levels according to clinical guidelines; the shaded area is the PK-profiling period and the arrow the start of surgery. The numbers in the graph display the given dose of the VWF/FVIII concentrate according to FVIII dose. (A) The real-life situation in which the patient was treated according to the clinical guidelines, with an initial dose of ~50 IU/kg followed by ~25 IU/kg every 12 hours. (B) The hypothetical situation in which the doses needed to achieve the target levels are calculated based on the individual PK parameters of the patient derived from the levels measured during an individual PK profile before surgery.

Generally, an FVIII half-life of 2 to 3 hours is observed in these patients, which approaches the FVIII half-life of 6.6 hours without VWF presence as observed in the present model.²⁸⁻³⁰ In literature, the VWF half-life is found to be between 12 and 15 hours.^{28,30} Similarly, Lethagen et al have described the VWF half-life to be 15.6 hours in a VWD population receiving this VWF/FVIII concentrate preoperatively.¹⁷ This is almost equivalent to the 13.9 hours we observed in our analyses. In our previously published population PK model, which only describes FVIII levels after perioperative treatment with this specific concentrate, we reported a FVIII volume of distribution of 3.28 L/70 kg and clearance of 0.038 L/70 kg per hour.¹⁹ With these PK parameters, a typical patient of 70 kg will have a FVIII half-life of 60 hours, which does not comply with the FVIII half-life of 12 hours as described in literature. As this newly developed population PK model presents PK parameters that approach values reported in literature, we assume to have captured the PK of FVIII after perioperative treatment with this VWF/FVIII concentrate more realistically.

During covariate analysis, several patient characteristics and surgical characteristics were identified that were able to explain

parts of the IIV in the PK parameters. The observed negative association between surgery duration and VWF clearance may indicate that more VWF is produced and/or released when a surgical intervention takes longer to perform. Higher VWF baseline was associated with more comorbidities as defined by an ASA classification of III or IV.²⁴ Atiq et al also observed the association between more comorbidities and increased VWF levels in patients with VWD. This report indicated that this association was most likely explained by increasing age, especially in patients with type 1 VWD.³¹ In our study, type of VWD was found to be associated with the baseline of VWF, which is consistent with the classification system of VWD types.² The high relative standard error value of the association between type 3 patients and the VWF baseline is probably caused by the small number of type 3 patients in this data set. We decided to maintain this covariate in the final model, as it properly displays the clinical difference between the types of patients with VWD. Finally, an association between FVIII clearance and VWD type was observed, indicating that type 2 and type 3 patients show decreased FVIII clearance. This observation feels contradictory, as

binding of VWF to FVIII is dysfunctional in patients with type 2N and endogenous VWF is normally not present in type 3 patients, causing enhanced FVIII clearance. However, exogenous FVIII and VWF may have different PK properties than endogenous FVIII and VWF, that is, the exogenous VWF administered in type 2N patients has no dysfunctional binding to FVIII and the presence of exogenous VWF possibly lowers the enhanced FVIII clearance seen in type 3 patients not treated with factor concentrates.

During model development, we chose to model the preadministration VWF and FVIII levels as endogenous baseline levels instead of the often lower historical (lowest ever measured) baseline level. The observed differences between the historical baseline and preadministration VWF and FVIII levels may be caused by multiple factors, such as preoperative stress, inflammation, increasing age, comorbidities, or analytical variation.^{15,16} If this difference is only a temporary increase caused by, for example, preoperative stress, factor levels will return to the historical baseline in the postoperative period. However, if increasing age or comorbidity is the underlying reason, levels will approach the preadministration level postoperatively as this reflects the current endogenous baseline. In the analysis, we assumed that the baseline difference is permanent, and caused by, for example, increasing age, as the FVIII level dropped below the preadministration level in only 1 surgical procedure, and the VWF:Act level dropped below the preadministration level in 3 procedures. These differences were small (<0.10 IU/mL). An endogenous baseline increase caused by increasing age is especially expected in type 1 patients with an VWF:Act baseline ≥ 0.10 IU/mL. For type 1 patients with a baseline <0.10 IU/mL as well as type 2 and type 3 patients, the endogenous baseline is expected to remain similar over time.³¹ In our data set, type 1 patients contributed most to the baseline differences (58%), but, surprisingly, other types of patients also showed an endogenous baseline increase compared with the historical baseline.

A limitation of this study is that type 2B ($n = 9$), type 2M ($n = 11$), type 2N ($n = 3$), and type 3 ($n = 6$) patients were underrepresented. Although goodness-of-fit plots show adequate prediction of the separate disease types (supplemental Figures 1-3) and VWF:Act and FVIII levels of the clinical case (type 3 VWD) were adequately described, application of the population PK model in these types of patients may be less accurate. Another limitation is that we were unable to distinguish endogenous from exogenous coagulation factors in the population PK model. Endogenous and exogenous FVIII and VWF may have different PK and, as a result, the model may be improved by estimation of separate PK parameters for both endogenous and exogenous coagulation factors. Unfortunately, it is not yet possible to measure these coagulation factors separately and it was necessary to model the change in the cumulative sum of the endogenous and exogenous VWF:Act and FVIII levels over time. A third limitation is the high relative standard error ($>30\%$) obtained for FVIII clearance in the final model, indicating that there is some uncertainty around the estimated value. Possibly, this can be solved by adding data with more level measurements per subject or by implementing a better sampling scheme. Finally, the population PK model was only based on data from patients receiving 1 particular VWF/FVIII concentrate. A study by Kessler et al showed bioequivalent VWF PK properties for 2 commonly used VWF/FVIII concentrates, but PK of FVIII after administration of the concentrates is different.³² Therefore, we recommend only using the model for patients receiving this specific

concentrate. For VWF/FVIII concentrates with other ratios or multimer compositions, other population PK models will have to be developed.

Clinical applicability of our newly developed model was demonstrated by the clinical case described in this manuscript. For this unique type 3 patient, higher VWF/FVIII concentrate doses would have been necessary to reach the prespecified targets, although, for the majority of patients, lower doses are expected to reach the targets (supplemental Figure 4). Undoubtedly, this single case does not confirm external validity of the model and external validation in a larger cohort is recommended. This case only demonstrates the clinical implications of PK-guided dosing using an interaction model. As clinical guidelines increasingly recommend monitoring and targeting both VWF and FVIII levels, this population PK model is beneficial over the previously developed population PK model based only on FVIII levels.^{1,19-21} Despite the fact that this population PK model will support the targeting of sufficient VWF and FVIII levels, it is important to realize that the VWF/FVIII ratio of this concentrate is fixed and that both coagulation factors have different PK properties. Therefore, it remains challenging to achieve FVIII and VWF levels within similar ranges, and sometimes it may be unavoidable to accept higher FVIII (or possibly VWF) levels when dosing repetitively. Future prospective studies that examine the feasibility and reliability of PK-guided dosing with VWF/FVIII concentrates in patients with perioperative VWD will further verify the validity of this PK-guided dosing approach and its clinical impact.

Conclusion

This novel integrated population PK model adequately describes VWF:Act and FVIII levels after perioperative dosing with a VWF/FVIII concentrate (ratio 2.4:1; Humate P/Haemate P). In this model, presence of VWF decreases FVIII clearance and increases FVIII half-life, thereby approaching a more physiological situation and explaining FVIII accumulation observed in this specific situation. Application of this model may facilitate PK-guided perioperative dosing with this specific concentrate based on both FVIII and VWF:Act targets, thereby potentially improving quality and cost-effectiveness of care.

Acknowledgment

L.H.B. was supported by a fund from the Netherlands Organisation for Scientific Research (NWO) in the framework of the Dutch Research Agenda—Research Along Routes by Consortia (NWA-ORC) Call Grant Agreement NWA.1160.18.038.

Authorship

Contribution: L.H.B., N.C.B.d.J., and R.A.A.M. analyzed the data by developing the population PK model; L.H.B. wrote the manuscript; J.M.H. and H.C.A.M.H. collected the clinical data; patient inclusion was monitored by H.C.A.M.H., K.F., K.M., J.C.J.E., B.A.P.L.-v.G., F.W.G.L., and M.H.C.; R.A.A.M. and M.H.C. supervised the study; F.W.G.L. gave critical guidance; and all authors contributed substantially to the critical revision of the manuscript and approved the final draft.

Conflict-of-interest disclosure: J.M.H. has received a grant from CSL Behring outside of the submitted work. K.F. has received unrestricted research grants from CSL Behring, Bayer, and Novo Nordisk, and has received institutional consultancy fees from Shire,

Roche, Novo Nordisk, and Bayer. B.A.P.L.-v.G. has received unrestricted educational grants from Baxter and CSL Behring. K.M. has received research support from Bayer, Sanquin, and Pfizer; speaker fees from Bayer, Sanquin, Boehringer Ingelheim, Bristol Myers Squibb (BMS), and Aspen; and consulting fees from uniQure. J.C.J.E. received research support from CSL Behring and has been a teacher for Roche, involved with its educational activities. F.W.G.L. received unrestricted research grants from CSL Behring, Shire/Takeda, Sobi, and uniQure; is a consultant for CSL Behring, Shire/Takeda, Biomarin, and uniQure, of which the fees go to the University; received travel support from Sobi; and is a Data and Safety Monitoring Board member of a study sponsored by Roche. M.H.C. has received grants from governmental research institutes such as the Dutch Research Institute (NWO), ZonMW, the Innovation Fund, and NWO-ORC; has received unrestricted investigator-initiated research grants as well as educational and travel funding from the following companies over the years: Pfizer, Baxter/Baxalta/Shire, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, and Nordic Pharma; and has served as a member on the steering boards of Roche and Bayer. All grants, awards, and fees go to the institution. R.A.A.M. has received grants from governmental and societal research institutes such as NWO, ZonMW, Kidney Foundation and Innovation Fund; unrestricted investigator research grants from Baxter/Baxalta/Shire/Takeda, Bayer, CSL Behring, Sobi, and CelltrionHC; and has served as advisor for Bayer, CSL Behring, Merck Sharp & Dohme, Baxter/Baxalta/Shire/Takeda. (All grants and fees were paid to the institution.) The remaining authors declare no competing financial interests.

A complete list of the members of the OPTI-CLOT Study Group appears in "Appendix."

ORCID profiles: L.H.B., 0000-0001-7967-1023; J.M.H., 0000-0003-1069-8097; K.F., 0000-0003-0904-4360; K.M., 0000-0001-9447-0465; M.H.C., 0000-0003-1557-2995.

Correspondence: Ron A. A. Mathôt, Amsterdam UMC, University of Amsterdam, PO 22660, 1100 DD Amsterdam, The Netherlands; e-mail: r.mathot@amsterdamumc.nl.

Appendix

This paper was written on behalf of the international multicentre "OPTI-CLOT" (patient tailored Pharmacokinetic-guided dosing of CLOTting factor concentrates in bleeding disorders) and "To Win" studies that aim to implement a PK-guided approach for the treatment of bleeding disorders using population PK models for desmopressin, factor concentrates, and other alternative drugs. Steering Committee: M.H.C. (principal investigator and chair), F.W.G.L., R.A.A.M. (co-leading investigator), K.F., M. Coppens (Amsterdam University Medical Centre), University Medical Centre Amsterdam, and K.M.

Principal investigators, local collaborators, and PhDs in The Netherlands: M. J. H. A. Kruip, S. Polinder, J. Lock, H. C. A. M. Hazendonk, I. van Moort, J. M. Heijdra, M. C. H. J. Goedhart, and W. Al Arashi (Erasmus MC, University Medical Center Rotterdam); T. Preijers, N.C.B.d.J., L.H.B., M. E. Cloesmeijer, and A. Janssen (Amsterdam University Medical Centre); K.M., and R. Y. J. Tamminga (University Medical Centre Groningen); P. Brons and S. E. M. Schols (Radboud University Medical Centre); H.C.J. (Leiden University Medical Centre); R. E. G. Schutgens, K. Fischer, and K. P. M. van Galen (University Medical Centre Utrecht); E. A. M. Beckers, and F. C. J. I. Heubel-Moenen (Maastricht University Medical Centre); L. Nieuwenhuizen (Maxima Medical Centre, Eindhoven); P. Ypma (Haga Hospital, The Hague); M. H. E. Driessens (The Netherlands Haemophilia Patient Society); Web site, trial bureau, and databases: M. Zwaan and I. van Vliet (Erasmus MC, University Medical Centre Rotterdam).

Principal investigators and local collaborators in the United Kingdom: P. W. Collins (Arthur Bloom Haemophilia Centre, Institute of Infection and Immunity, School of Medicine, Cardiff University); R. Liesner (Great Ormond Street Haemophilia Centre, Great Ormond Street Hospital for Children NHS Trust, London); P. Chowdary (Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free London NHS Foundation Trust, London); C. M. Millar (Hammersmith Hospital-Imperial College Healthcare NHS Trust, London); D. Hart (Department of Haematology, The Royal London Hospital Barts Health NHS Trust, London); D. Keeling (Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals, Churchill Hospital, Oxford).

References

- Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). *Haemophilia*. 2008;14(2):171-232.
- Leebeek FWG, Eikenboom JCJ. Von Willebrand's disease. *N Engl J Med*. 2016;375(21):2067-2080.
- Sadler JE, Budde U, Eikenboom JCJ, et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. *J Thromb Haemost*. 2006;4(10):2103-2114.
- Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). *J Thromb Haemost*. 2003;1(4):682-689.
- Heijdra JM, Cnossen MH, Leebeek FWG. Current and emerging options for the management of inherited von Willebrand disease. *Drugs*. 2017;77(14):1531-1547.
- Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. *J Thromb Haemost*. 2005;3(10):2219-2227.
- Gill JC, Castaman G, Windyga J, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease [published correction appears in *Blood*. 2016;127(22):2777]. *Blood*. 2015;126(17):2038-2046.
- Wells PS, Langlois NJ, Webster MA, Jaffey J, Anderson JA. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada – is it necessary to define a new upper reference range for factor VIII? *Thromb Haemost*. 2005;93(5):842-846.

9. Mannucci PM. Treatment of von Willebrand's disease. *N Engl J Med*. 2004;351(7):683-694.
10. Srivastava A, Serban M, Werner S, Schwartz BA, Kessler CM; Wonders Study Investigators. Efficacy and safety of a VWF/FVIII concentrate (Wilate[®]) in inherited von Willebrand disease patients undergoing surgical procedures. *Haemophilia*. 2017;23(2):264-272.
11. Raquet E, Stockschröder M, Dickneite G. Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model. *Haemophilia*. 2011;17(5):808-814.
12. Berntorp E. Haemate P/Humate-P: a systematic review. *Thromb Res*. 2009;124(suppl 1):S11-S14.
13. Kouides P, Wawra-Hehenberger K, Sajan A, Mead H, Simon T. Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data. *Transfusion*. 2017;57(10):2390-2403.
14. Hazendonk HCAM, Heijdra JM, de Jager NCB, et al; "OPTI-CLOT" and "WIN" study group. Analysis of current perioperative management with Haemate[®] P/Humate P[®] in von Willebrand disease: identifying the need for personalized treatment. *Haemophilia*. 2018;24(3):460-470.
15. Gill JC, Shapiro A, Valentino LA, et al. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. *Haemophilia*. 2011;17(6):895-905.
16. Franchini M. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage. *Blood Transfus*. 2008;6(suppl 2):s33-s38.
17. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. *J Thromb Haemost*. 2007;5(7):1420-1430.
18. Di Paola J, Lethagen S, Gill J, et al. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery. *Haemophilia*. 2011;17(5):752-758.
19. de Jager NCB, Bukkems LH, Heijdra JM, et al; OPTI-CLOT group. One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P[®]/Humate P[®] treatment in von Willebrand disease patients. *J Thromb Haemost*. 2020;18(2):295-305.
20. Nederlandse Vereniging van Hemofiliebehandelaars (NVHB). *Richtlijn: Diagnostiek en Behandeling van Hemofilie en Aanverwante Hemostasestoornissen*. Utrecht, The Netherlands: NVHB; 2009.
21. Laffan MA, Lester W, O'Donnell JS, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. *Br J Haematol*. 2014;167(4):453-465.
22. Bauer A, Wolfsegger MJ. Adjustment of endogenous concentrations in pharmacokinetic modeling. *Eur J Clin Pharmacol*. 2014;70(12):1465-1470.
23. Gabrielsson J, Weiner D. *Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications*. Stockholm, Sweden: Swedish Pharmaceutical Society; 2000.
24. Abouleish AE, Leib ML, Cohen NH. ASA provides examples to each ASA physical status class. *ASA Monitor*. 2015;79:38-39.
25. Koshy M, Weiner SJ, Miller ST, et al; Cooperative Study of Sickle Cell Diseases. Surgery and anesthesia in sickle cell disease. *Blood*. 1995;86(10):3676-3684.
26. van Dijk K, van der Bom JG, Lenting PJ, et al. Factor VIII half-life and clinical phenotype of severe hemophilia A. *Haematologica*. 2005;90(4):494-498.
27. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. *Eur J Clin Pharmacol*. 2009;65(10):989-998.
28. Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. *Blood*. 2016;128(16):2007-2016.
29. Tuddenham EGD, Lane RS, Rotblat F, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. *Br J Haematol*. 1982;52(2):259-267.
30. Mazurier C, Gaucher C, Jorieu X, Goudemand M; Collaborative Group. Biological effect of desmopressin in eight patients with type 2N ("Normandy") von Willebrand disease. *Br J Haematol*. 1994;88(4):849-854.
31. Atiq F, Meijer K, Eikenboom J, et al; WiN study group. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. *Br J Haematol*. 2018;182(1):93-105.
32. Kessler CM, Friedman K, Schwartz BA, Gill JC, Powell JS; Wilate PK Study Investigators. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study. *Thromb Haemost*. 2011;106(2):279-288.